Michael Tees MD, MPH

Lymphoma Program Director, Colorado Blood Cancer Institute #lymphoma #lymsm #celltherapy #CART #autoimmune #BMT @CBCIDocs @ColoradoBlood 🏳️‍🌈 opinions my own

[Michael Tees MD, MPH @MikeTeesMD]

Thanks Lina with @Hickenlooper and Tara with @SenatorBennet for your time today from CO @LLSAdvocacy. Support of #AKACA and clinical trial diversity 🏆 for all #LLSAction

[Michael Tees MD, MPH @MikeTeesMD]

Thank you Nimit with ⁦@RepDianaDeGette⁩ ⁦@LLSAdvocacy⁩ for clinical trial diversity and allowing patients to get the care they need #LLSAction

[Michael Tees MD, MPH @MikeTeesMD]

Thanks Ben with Rep @YadiraCaraveo for meeting with @BarryGGore5280 @dduchateauco and @LLSAdvocacy on lobby day #LLSAction helping children and improving trial diversity

[Michael Tees MD, MPH @MikeTeesMD]

Thank you Ryan @RepJoeNeguse for meeting with @dduchateauco @BarryGGore5280 and @LLSAdvocacy on behalf of patients to improve access to care #LLSaction

[Michael Tees MD, MPH @MikeTeesMD]

⁦@dduchateauco @barryggore5280 ⁦@LLSAdvocacy⁩ #LLSAction for CO patients on Capitol Hill

[Michael Tees MD, MPH @MikeTeesMD]

Clinical trials are a lifeline for cancer patients. But for many—especially patients in underrepresented groups—they’re out of reach. Urge lawmakers to support the NIH Clinical Trial Diversity Act to ensure all patients get the care they need: https://t.co/22JA2CbcxY #LLSAction

[Michael Tees MD, MPH @MikeTeesMD]

Clinical trials are a lifeline for cancer patients. But for too many, they're out of reach. Congress can help ensure that all patients have access to trials. Tell your lawmakers to act now – before it's too late ⌛ https://t.co/22JA2CbKnw #LLSAction

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Just out in @BloodAdvances Lee by our own Dr Nitin Jain @NitinJainMD & Dr Bill Wierda @wwierda ➡️ Ph2 results Nivo+IBR for patients with DLBCL-RT of CLL. @MDAndersonNews #leusm #endcancer
https://t.co/IobH2hskZR 📣

[Michael Tees MD, MPH @MikeTeesMD]

#Tandem23 woohoo made it

[NMDP @nmdp_org]

What a special moment on @GMA this morning when @RobinRoberts surprised the nurses who were by her side 10 years ago during her bone marrow transplant journey. 💙💚

Check out their heartwarming reunion 👇

[Michael Tees MD, MPH @MikeTeesMD]

Yes totally agree. MTX containing induction + TT containing auto #bmtsm for PCNSL & ph3 data proving it! #lymphoma #lymsm #ASH22

[Mehdi Hamadani, MD @MediHumdani]

#ASH22 LBA HDT Auto vs NMAchemo in PCNSL MATRiX @OncLive both PFS & OS in favor of AutoHCT with bcnu/TT #bmtsm #lymsm practice validating study

[Michael Tees MD, MPH @MikeTeesMD]

Amazing #ASH22 in #NOLA ⭐️ ⭐️ ⭐️ ⭐️ ⭐️ Can’t wait for #ASH23

[Adam Kittai @AdamKittai]

Median PFS for pirtobrutinib after btki and bcl2i is 16.8 months. Safe, and effective. Very nice to see. #CLL #ASH22

[Aaron Logan, MD, PhD, MPhil @hemedoc]

#ASH22 #leusm Reville: CLIA-Ven is a great regimen but still could benefit from additional optimization due to prolonged cytopenias during consolidation cycles and associated infections.

[Michael Tees MD, MPH @MikeTeesMD]

CD20x3 BiTE: #dlbcl Epco + DHAOx/C -> auto #BMTsm = 80% CR!!!! #lymphoma #lymsm #ASH22
https://t.co/AVZcqE6YVw

[Michael Tees MD, MPH @MikeTeesMD]

Somewhat argues to pre-bridge (pola-R) to get to “2L” #CART #DLBCL. Often have to anyway… #Lymphoma #lymsm #ASH22 @DrFredLocke https://t.co/TnwAyO6lDL

[Michael Tees MD, MPH @MikeTeesMD]

old and new BTKis are having a moment - in the CNS 🧠 💫 #lymphoma #lymsm #ASH22

[Michael Tees MD, MPH @MikeTeesMD]

Transplant adult Ph+ALL in CR1? Compelling to wait if able to give peds induction regimen (and TKI)… #ALL #leusm #BMTsm #ASH22
https://t.co/ypeeisSSEN

[Alexandra Rezazadeh, MD @RazzleMD]

Feeling special 🤩🤩🤩 #ASHPresidentsDinner #ASH22

[Michael Tees MD, MPH @MikeTeesMD]

Calculators out. Metabolic tumor volume (> 200 cm3) prognosticates. With FLIPI2, another tool in follicular #lymphoma #lymsm #ASH22
https://t.co/P13GmoY4dp